According to a small study by Weill Cornell Medicine and New York-Presbyterian investigators, vaccinating mothers using Pfizer Inc's (NYSE:PFE) vaccine against respiratory syncytial virus (RSV) during late pregnancy to protect their newborns is not associated with an increased risk of preterm birth or other poor outcomes.
The FDA approved the Abrysvo (RSVpreF) vaccine last year. It targets women in their second or third trimesters to prevent RSV infections in newborns during their first six months.
Also Read: UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract.
In September 2023, the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recommended the RSVpreF vaccine be administered to most pregnant individuals from September to January in the U.S.
This is in contrast to GSK Plc's (NYSE:GSK) RSV adjuvanted vaccine, which is not approved for use in pregnant individuals based on a trial that was terminated early due to an elevated risk of premature birth and associated neonatal deaths.
Although the FDA approved the RSVpreF vaccine, the gestational age window was limited to 32 0/7 to 36 6/7 weeks due to concerns about the numerical difference in preterm birth among participants who received the RSVpreF vaccine from 24 to 36 weeks gestation.
The findings indicated no significant statistical difference in preterm birth rates, with vaccinated women showing a rate of 5.9%, compared to 6.7% in unvaccinated women.
The study analyzed electronic health records from two New York City hospitals, focusing on births from September 2023 to late January 2024.
Data published in the Jama Network comes from 2,973 pregnant individuals. The researchers add that though the data support the safety of prenatal RSVpreF vaccination, further investigation into the risk of hypertensive disorders of pregnancy (HDP) is warranted.
Price Action: PFE shares are down 0.60% at $27.88 at the last check on Monday.
- CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK.
Photo via Shutterstock
根據Weill Cornell Medicine和紐約長老會調查人員進行的一項小型研究，母親在妊娠晚期使用輝瑞公司（紐約證券交易所代碼：PFE）的呼吸道合胞病毒（RSV）疫苗接種以保護新生兒與早產風險增加或其他不良預後無關。
美國食品藥品管理局去年批准了Abrysvo（RsvPref）疫苗。它針對的是孕中期或晚期的女性，以防止新生兒在頭六個月內感染呼吸道合胞病毒。
另請閱讀：英國選擇輝瑞而不是葛蘭素史克簽訂數百萬劑量的呼吸道合約。
2023年9月，美國疾病控制與預防中心的免疫實踐諮詢委員會建議，在9月至1月，在美國向大多數孕婦接種RSVPref疫苗。
這與葛蘭素史克公司（紐約證券交易所代碼：GSK）的呼吸道合胞病毒輔助疫苗形成鮮明對比。根據一項試驗，該試驗因早產和相關新生兒死亡的風險升高而提前終止，該疫苗未獲準用於孕婦。
儘管美國食品和藥物管理局批准了RSVPref疫苗，但由於擔心在妊娠24至36周之間接種RSVPref疫苗的參與者之間的早產數字差異，胎齡窗口限制在32 0/7至36 6/7周以內。
研究結果表明，早產率沒有顯著的統計差異，接種疫苗的女性的早產率爲5.9％，而未接種疫苗的女性的早產率爲6.7％。
該研究分析了紐約市兩家醫院的電子健康記錄，重點是2023年9月至2024年1月下旬的出生情況。
Jama網絡上發佈的數據來自2973名孕婦。研究人員補充說，儘管數據支持產前RsvPref疫苗的安全性，但有必要進一步調查妊娠期高血壓障礙（HDP）的風險。
價格走勢：週一最後一次支票時，PFE股價下跌0.60％，至27.88美元。
- CDC顧問小組建議美國75歲以上人群接種呼吸道合胞病毒疫苗，分析師稱GsK的決定是否定的。
照片來自 Shutterstock
